HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Lowers Price Target to $67
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price target from $68 to $67.
HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price target from $68 to $67.